The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World Comment

The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (C) 2021 Elsevier HS Journals, Inc.

Automated summary

The approval and use of COVID-19 vaccines, including mRNA vaccines and recombinant adenovirus vaccines, have brought hope for ending the pandemic by producing the Spike protein of SARS-CoV-2 using new vaccine production platforms. However, there are still challenges in controlling the outbreak.